Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Biogen, Eisai's...

    Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

    Written by Ruby Khatun Khatun Published On 2018-07-06T10:00:22+05:30  |  Updated On 6 July 2018 10:00 AM IST
    Biogen, Eisais Alzheimers drug succeeds in mid-stage trial, shares soar

    Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer’s drug showed positive results for patients who received the highest dose.


    The news sent Eisai’s shares up as much as 14.6 percent in Friday morning trading in Tokyo while Biogen’s shares were up 7 percent at $320 in after-hours trading.


    The companies said in a July 5 statement the highest dose of the drug, BAN2401, showed a statistically significant slowing of disease progression at the end of 18 months as compared to a placebo. The trial, which involved 856 patients with early Alzheimer’s disease, involved five dose regimens.


    Biogen, based in Cambridge, Massachusetts, last December reported that the drug had failed to meet the main goal in the mid-stage trial, but said the 18-month trial would continue for further analysis.


    Biogen and Eisai said in their statement on Thursday that detailed results of the final analysis of the mid-stage trial will be released at future conferences.


    BAN2401 is one of a number of drugs targeting beta-amyloid, a protein that forms toxic brain plaques that are theoretically an underlying cause of the memory-robbing disease.


    There is still no treatment that can slow the progression of Alzheimer’s, the commonest form of dementia. Current drugs can do no more than ease some of the symptoms.


    The two drugmakers are also developing another Alzheimer’s drug, aducanumab.


    (Reporting by Anirban Paul in Bengaluru and Sam Nussey in Tokyo; Editing by Leslie Adler and Muralikumar Anantharaman)

    aducanumabAlzheimer's drugBAN2401BiogenEisaimid-stage trialsucceeds
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok